Alice C Ceacareanu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1445447/publications.pdf

Version: 2024-02-01

20 papers

218 citations

1683354 5 h-index 996533 15 g-index

20 all docs

20 docs citations

20 times ranked 379 citing authors

#	Article	IF	Citations
1	pH-Sensitive brush polymer-drug conjugates by ring-opening metathesis copolymerization. Chemical Communications, 2011, 47, 4493.	2.2	95
2	Counter-Regulatory Function of Protein Tyrosine Phosphatase 1B in Platelet-Derived Growth Factor– or Fibroblast Growth Factor–Induced Motility and Proliferation of Cultured Smooth Muscle Cells and in Neointima Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 501-507.	1.1	52
3	Insulin use, adipokine profiles and breast cancer prognosis. Cytokine, 2017, 89, 45-61.	1.4	18
4	Synergistic Benefit of Statin and Metformin in Gastrointestinal Malignancies. Journal of Pharmacy Practice, 2017, 30, 185-194.	0.5	13
5	Missing the benefit of metformin in acute myeloid leukemia: A problem of contrast?. Journal of Research in Pharmacy Practice, 2017, 6, 145.	0.2	12
6	Circulating adipokines data associated with insulin secretagogue use in breast cancer patients. Data in Brief, 2017, 10, 238-247.	0.5	5
7	Sexual dimorphism, weight gain and glucose intolerance in a B- and T-cell deficient mouse model. Cytokine, 2014, 67, 102-106.	1.4	3
8	A Pharmacist's Perspective on Metformin Use and Cancer Outcomes. Journal of Pharmacy Practice, 2015, 28, 44-45.	0.5	3
9	TH1 and TH2 cytokines dataset in insulin users with diabetes mellitus and newly diagnosed breast cancer. Data in Brief, 2017, 11, 331-348.	0.5	3
10	Management of Comorbidities in Diabetics With Renal Cell Carcinoma. Journal of Pharmacy Practice, 2014, 27, 31-39.	0.5	2
11	Dataset on growth factor levels and insulin use in patients with diabetes mellitus and incident breast cancer. Data in Brief, 2017, 11, 183-191.	0.5	2
12	Dataset on granulopoiesis- and lymphopoiesis-stimulating cytokine levels in insulin secretagogue users with incident breast cancer. Data in Brief, 2017, 11, 277-283.	0.5	2
13	Insulin use, hormone receptor status and hematopoietic cytokines \times^3 circulation in women with diabetes mellitus and breast cancer. Data in Brief, 2017, 11, 382-390.	0.5	2
14	Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer. Data in Brief, 2017, 11, 459-468.	0.5	2
15	Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer. Data in Brief, 2017, 11, 446-458.	0.5	2
16	TH1 and TH2 cytokine data in insulin secretagogues users newly diagnosed with breast cancer. Data in Brief, 2017, 11, 413-427.	0.5	1
17	Insulin secretagogue use and circulating inflammatory C–C chemokine levels in breast cancer patients. Data in Brief, 2017, 11, 391-402.	0.5	1
18	Evaluation of parameters for treatment duration of sunitinib in metastatic renal cell carcinoma Journal of Clinical Oncology, 2012, 30, e15042-e15042.	0.8	0

#	Article	IF	CITATIONS
19	Inflammation and sexual dimorphism in development of insulin resistance: a dual animal model comparison. FASEB Journal, 2013, 27, 918.2.	0.2	O
20	Application of a Pharmacokinetic Model of Metformin Clearance in a Population with Acute Myeloid Leukemia. Journal of Research in Pharmacy Practice, 2018, 7, 41-45.	0.2	0